Insiders · BBOT

BBOT insider transactions

BridgeBio Oncology Therapeutics Inc. (BBOT) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

Recent Form 3, 4, and 5 filings for BBOT

• 22d
  SEC Form 4 filed by COO & Principal Financial Ofcr Elmelech Idan

  4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
• 22d
  SEC Form 4 filed by President and CEO Beltran Pedro

  4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
• 28d
  Chief Med & Dev Officer Ben Yong covered exercise/tax liability with 1,047 shares, decreasing direct ownership by 2% to 45,623 units (SEC Form 4) to satisfy withholding tax

  4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
• 28d
  President and CEO Beltran Pedro covered exercise/tax liability with 1,047 shares, decreasing direct ownership by 2% to 45,623 units (SEC Form 4) (tax liability)

  4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
• 28d
  Former Officer Mehra Uneek covered exercise/tax liability with 524 shares, decreasing direct ownership by 2% to 22,806 units (SEC Form 4) to satisfy withholding tax

  4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
• 34d
  New insider Cobo Marc claimed ownership of 5,431 shares (SEC Form 3)

  3 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
• 34d
  New insider Elmelech Idan claimed ownership of 14,838 shares (SEC Form 3)

  3 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
• 69d
  SEC Form 4 filed by Lebowitz Peter F

  4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
• 69d
  SEC Form 3 filed by new insider Lebowitz Peter F

  3 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
• 83d
  Chief Financial Officer Mehra Uneek was granted 23,330 shares (SEC Form 4)

  4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
• 83d
  Chief Scientific Officer Beltran Pedro was granted 46,670 shares (SEC Form 4)

  4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
• 83d
  Chief Med & Dev Officer Ben Yong was granted 46,670 shares (SEC Form 4)

  4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
• 148d
  SEC Form 4 filed by Chief Executive Officer Wallace Eli M.

  4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
• 172d
  SEC Form 4 filed by Chief Executive Officer Wallace Eli M.

  4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
• 230d
  Large owner Bridgebio Pharma Llc acquired 784,720 shares (SEC Form 4)

  4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
• 240d
  SEC Form 4 filed by Chief Executive Officer Wallace Eli M.

  4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)